Twist Bioscience (TWST) to Release Quarterly Earnings on Friday

Twist Bioscience (NASDAQ:TWST) is expected to announce its Q4 2025 results before the market opens on Friday, November 14th. Analysts expect Twist Bioscience to post earnings of ($0.40) per share and revenue of $97.40 million for the quarter. Investors can check the company’s upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Friday, November 14, 2025 at 8:00 AM ET.

Twist Bioscience Stock Performance

Shares of TWST opened at $31.87 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience has a 1 year low of $24.07 and a 1 year high of $55.33. The firm has a fifty day moving average of $29.63 and a 200-day moving average of $31.50. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -21.98 and a beta of 2.43.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of recent analyst reports. Stephens assumed coverage on Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target on the stock. Barclays reduced their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, October 2nd. Evercore ISI lowered their price target on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.80.

Insider Buying and Selling

In related news, SVP Paula Green sold 9,724 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $313,015.56. Following the completion of the transaction, the senior vice president owned 114,678 shares of the company’s stock, valued at approximately $3,691,484.82. This trade represents a 7.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 5,875 shares of the business’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $189,116.25. Following the sale, the chief financial officer directly owned 97,042 shares in the company, valued at approximately $3,123,781.98. This trade represents a 5.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 122,865 shares of company stock valued at $3,879,926. Insiders own 3.01% of the company’s stock.

Institutional Trading of Twist Bioscience

Institutional investors have recently made changes to their positions in the stock. Balyasny Asset Management L.P. raised its holdings in Twist Bioscience by 934.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock worth $23,113,000 after acquiring an additional 567,481 shares during the period. Bank of America Corp DE increased its stake in shares of Twist Bioscience by 143.4% in the second quarter. Bank of America Corp DE now owns 688,332 shares of the company’s stock worth $25,324,000 after purchasing an additional 405,560 shares during the period. Soleus Capital Management L.P. acquired a new position in shares of Twist Bioscience during the 2nd quarter worth about $13,038,000. Qube Research & Technologies Ltd boosted its stake in Twist Bioscience by 38.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 331,181 shares of the company’s stock valued at $12,184,000 after purchasing an additional 91,783 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Twist Bioscience by 8.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 790,893 shares of the company’s stock valued at $22,252,000 after buying an additional 62,300 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.